Form 6-K ImmunoPrecise Antibodies For: Sep 02
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2025.
Commission File Number: 001-39530
ImmunoPrecise Antibodies Ltd.
Industrious 823 Congress Ave Suite 300 Austin, Texas 78701
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ |
Form 40-F ☐ |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
IMMUNOPRECISE ANTIBODIES LTD. |
|
Date: September 2, 2025 |
|
|
|
|
|
|
By: |
/s/ Jennifer Bath
|
|
Name: |
Jennifer Bath |
|
Title: |
President and Chief Executive Officer |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Future Electrified Luxury Arrives in Arizona: Preview the 2027 Electric Mercedes-Benz GLC SUV
- OFA Group Receives Additional 180-Day Nasdaq Compliance Period; Nasdaq Confirms Company Remains Compliant with All Continued Listing Standards Other Than the Minimum Bid Price Requirement
- MADD Canada to Honour Newfoundland and Labrador Police Officers for Outstanding Impaired Driving Enforcement
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
